Chou, W
All referenced data reflects preclinical and investigational findings from in vitro, ex vivo, and cell culture experimental models
First, their GLP-1 ID protocol
It is often prescribed for conditions like primary and secondary L-Carnitine deficiencies, which can be due to genetic disorders, dialysis, certain medications, or other medical conditions that deplete the body's L-Carnitine stores
The data revealed that while participants treated with semaglutide did lose absolute lean mass, they lost a significantly larger amount of fat mass
Media coverage, online discussions, and high-profile public conversations around weight loss treatments have introduced GLP-1 therapy to a much wider audience than in the past